1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | Hel; Human ErythroLeukemia |
| Species | Human |
| Cat.No | ABL-TC0248 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocyte-like |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Leukemia Cell Lines |
HEL is a human erythroleukemia cell line established from the peripheral blood of a 30-year-old Caucasian male who developed therapy-related erythroleukemia following relapse after Hodgkin’s lymphoma treatment. These cells exhibit lymphoblastoid-like morphology and grow predominantly in suspension, although a subset may demonstrates semi-adherent properties in culture. HEL has a doubling time of approximately 24 – 36 hours. HEL harbors the JAK2 V617F mutation, commonly associated with myeloproliferative neoplasms. It expresses a range of surface antigens, including CD13, CD33, CD41a, CD71, and CD235a, as well as HLA A3, Aw32 and Bw35. In vivo studies confirm its tumorigenic potential, with subcutaneous or intravenous inoculation in immunodeficient mice. HEL serves as a model for studying erythroid differentiation and globin gene regulation, and leukemogenesis.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
HEL cells serve as a versatile model for investigating the mechanisms governing erythroid lineage differentiation and the regulation of globin gene expression. They serve as a valuable tool for assessing potential therapeutic interventions targeting erythroleukemia, including strategies aimed at inducing apoptosis or modulating JAK-STAT signaling. Given the presence of the JAK2 V617F mutation, HEL cells contribute significantly in dissecting the molecular pathways implicated in myeloproliferative neoplasms, aiding in the development of targeted therapies. Furthermore, it provide a robust model for drug screening, signal transduction studies, and understanding the hematopoietic effects of various pharmacologic agents.
